WO2002072086A3 - Use of epigallocatechin-3-gallate or its derivatives in the prevention and treatment of neurodegenerative diseases - Google Patents

Use of epigallocatechin-3-gallate or its derivatives in the prevention and treatment of neurodegenerative diseases Download PDF

Info

Publication number
WO2002072086A3
WO2002072086A3 PCT/IT2002/000149 IT0200149W WO02072086A3 WO 2002072086 A3 WO2002072086 A3 WO 2002072086A3 IT 0200149 W IT0200149 W IT 0200149W WO 02072086 A3 WO02072086 A3 WO 02072086A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
prevention
derivatives
neurodegenerative diseases
gallate
Prior art date
Application number
PCT/IT2002/000149
Other languages
French (fr)
Other versions
WO2002072086A2 (en
WO2002072086A8 (en
Inventor
Hisanori Suzuki
Original Assignee
Consorzio Per Gli Studi Uni
Hisanori Suzuki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consorzio Per Gli Studi Uni, Hisanori Suzuki filed Critical Consorzio Per Gli Studi Uni
Priority to AU2002247973A priority Critical patent/AU2002247973A1/en
Priority to EP02717053A priority patent/EP1411920A2/en
Publication of WO2002072086A2 publication Critical patent/WO2002072086A2/en
Publication of WO2002072086A8 publication Critical patent/WO2002072086A8/en
Publication of WO2002072086A3 publication Critical patent/WO2002072086A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

An epigallocatechni-3-gallate compound with the following formula (I), or its derivatives, is used for the prevention and treatment of neurodegenerative diseases, like for example of Parkinson's disease, Alzheimer's disease, Creutzfeld-Jacob syndrome, sleeping sickness caused by protozoa, including Trypanosoma brucei rhodensiense and Trypanosoma brucei gambiense, as well as for the treatment of asthma, diabetes, cardiovascular diseases, obesity.
PCT/IT2002/000149 2001-03-12 2002-03-11 Use of epigallocatechin-3-gallate or its derivatives in the prevention and treatment of neurodegenerative diseases WO2002072086A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002247973A AU2002247973A1 (en) 2001-03-12 2002-03-11 Use of epigallocatechin-3-gallate or its derivatives in the prevention and treatment of neurodegenerative diseases
EP02717053A EP1411920A2 (en) 2001-03-12 2002-03-11 Use of epigallocatechin-3-gallate or derivatives thereof in the prophylaxis and treatment of neurodegenerative diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITVR2001A000031 2001-03-12
IT2001VR000031A ITVR20010031A1 (en) 2001-03-12 2001-03-12 USE OF EPIGALLOCATECHIN-3-GALLATO OR ITS DERIVATIVES IN THE PROPHYLAXIS AND TREATMENT OF NEURODEGENERATIVE DISEASES.

Publications (3)

Publication Number Publication Date
WO2002072086A2 WO2002072086A2 (en) 2002-09-19
WO2002072086A8 WO2002072086A8 (en) 2002-10-10
WO2002072086A3 true WO2002072086A3 (en) 2004-02-19

Family

ID=11461977

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT2002/000149 WO2002072086A2 (en) 2001-03-12 2002-03-11 Use of epigallocatechin-3-gallate or its derivatives in the prevention and treatment of neurodegenerative diseases

Country Status (4)

Country Link
EP (1) EP1411920A2 (en)
AU (1) AU2002247973A1 (en)
IT (1) ITVR20010031A1 (en)
WO (1) WO2002072086A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006508096A (en) * 2002-11-07 2006-03-09 ディーエスエム アイピー アセッツ ビー．ブイ． A novel nutritional supplement composition containing epigallocatechin gallate
KR20050071709A (en) * 2002-11-28 2005-07-07 디에스엠 아이피 어셋츠 비.브이. Nutraceutical compositions comprising epigallocatechin gallate and raspberry ketone
US7491699B2 (en) 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
WO2004060791A1 (en) 2003-01-07 2004-07-22 Ramot At Tel Aviv University Ltd. Peptide nanostructures encapsulating a foreign material and method of manufacturing same
CN100518733C (en) * 2003-09-23 2009-07-29 帝斯曼知识产权资产管理有限公司 Compositions for the treatment and prevention of diabetes mellitus
CA2540407A1 (en) * 2003-09-25 2005-03-31 Tel Aviv University Future Technology Development L.P. Compositions and methods using same for treating amyloid-associated diseases
WO2006013552A2 (en) 2004-08-02 2006-02-09 Ramot At Tel Aviv University Ltd. Articles of peptide nanostructures and method of forming the same
US7732479B2 (en) 2004-08-19 2010-06-08 Tel Aviv University Future Technology Development L.P. Compositions for treating amyloid associated diseases
US20100040558A1 (en) * 2005-04-26 2010-02-18 University Of South Florida Green tea polyphenol alpha secretase enhancers and methods of use
US10004828B2 (en) 2005-10-11 2018-06-26 Romat at Tel-Aviv University Ltd. Self-assembled Fmoc-ff hydrogels
JP5576694B2 (en) * 2009-04-10 2014-08-20 花王株式会社 GIP elevation inhibitor
JP2016516082A (en) 2013-03-20 2016-06-02 アプトース バイオサイエンシーズ， インコーポレイテッド 2-Substituted imidazo [4,5-D] phenanthroline derivatives and their use in the treatment of cancer
WO2019236521A1 (en) * 2018-06-07 2019-12-12 Avanti Biosciences, Inc. Methods and formulations for intranasal administration

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5318986A (en) * 1989-10-19 1994-06-07 Mitsui Norin Co., Ltd. Method of inhibiting the activity of α-amylase
US5605929A (en) * 1992-05-27 1997-02-25 Arch Development Corp. Methods and compositions for inhibiting 5α-reductase activity
DE19627344A1 (en) * 1996-07-01 1998-01-08 Vitasyn Gmbh Entwicklung & Ver Therapeutic composition containing epicatechin and/or theaflavin
WO1999022728A1 (en) * 1997-10-31 1999-05-14 Arch Development Corporation Methods and compositions for regulation of 5-alpha reductase activity
US5922756A (en) * 1998-02-14 1999-07-13 Chan; Marion Man-Ying Method of inhibiting nitric oxide synthase
WO2000006171A1 (en) * 1998-07-31 2000-02-10 Hme Enterprises, Llc Antioxidant composition and method of treating diseases using same
WO2001049285A1 (en) * 2000-01-03 2001-07-12 Slk Foundation Flavonoid drug and dosage form, its production and use

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5318986A (en) * 1989-10-19 1994-06-07 Mitsui Norin Co., Ltd. Method of inhibiting the activity of α-amylase
US5605929A (en) * 1992-05-27 1997-02-25 Arch Development Corp. Methods and compositions for inhibiting 5α-reductase activity
DE19627344A1 (en) * 1996-07-01 1998-01-08 Vitasyn Gmbh Entwicklung & Ver Therapeutic composition containing epicatechin and/or theaflavin
WO1999022728A1 (en) * 1997-10-31 1999-05-14 Arch Development Corporation Methods and compositions for regulation of 5-alpha reductase activity
US5922756A (en) * 1998-02-14 1999-07-13 Chan; Marion Man-Ying Method of inhibiting nitric oxide synthase
WO2000006171A1 (en) * 1998-07-31 2000-02-10 Hme Enterprises, Llc Antioxidant composition and method of treating diseases using same
WO2001049285A1 (en) * 2000-01-03 2001-07-12 Slk Foundation Flavonoid drug and dosage form, its production and use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LEE, S.-R. ET AL.: "Protective effects of the green tea polyphenol (-)-epigallocatechin gallate against hippocampal neuronal damage after transient global ischemia in gerbils", NEUROSCIENCE LETTERS, vol. 287, no. 3, 30 June 2000 (2000-06-30), pages 191 - 194, XP002201223 *

Also Published As

Publication number Publication date
ITVR20010031A1 (en) 2002-09-12
EP1411920A2 (en) 2004-04-28
AU2002247973A1 (en) 2002-09-24
ITVR20010031A0 (en) 2001-03-12
WO2002072086A2 (en) 2002-09-19
WO2002072086A8 (en) 2002-10-10

Similar Documents

Publication Publication Date Title
NL300933I2 (en) Letermovir
CA2474578A1 (en) Novel pyridin- and pyrimidin-derivatives
WO2002072086A3 (en) Use of epigallocatechin-3-gallate or its derivatives in the prevention and treatment of neurodegenerative diseases
CA2443724A1 (en) Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
CA2430601A1 (en) Piperazine derivatives
HK1066790A1 (en) Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes
WO2006122186A3 (en) 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia
SI2527315T1 (en) Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes and Parkinson's disease
CA2472954A1 (en) Aza-arylpiperazines
WO2002092026A3 (en) Dermatological and cosmetic compositions
WO2004072031A8 (en) Phenylacetamides and their use as glucokinase modulators
CA2429844A1 (en) Mch antagonists and their use in the treatment of obesity
WO2002036562A3 (en) 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
WO2002078745A3 (en) Use of mglur5 antagonists in the manufacture of a medicament in the treatment of autism, mental retardation, schizophrenia
BR0316723A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
WO2006044762A3 (en) Tetrahydro-5h-pyrimido[4,5-d]azepine derivatives useful for the treatment of diseases associated with the 5-ht2c receptor
CA2474511A1 (en) Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders
WO2004082706A3 (en) Ifn-beta alone or in combination with other medicaments for treating alzheimer's disease and demens disorders
WO2003015780A3 (en) Isoxazolopyridinones and use thereof in the treatment of parkinson's disease
EP1944027A4 (en) Pharmaceutical composition for treatment or prevention of nephritis and method for producing same
YU12003A (en) Novel aminocyclohexane derivatives
WO2004022540A3 (en) Pyridazinone and pyridone derivatives as adenosine antagonists
MXPA04005907A (en) Heteroaryl-substituted aminocyclohexane derivatives.
AU2003289652A1 (en) The use of compound helicid for manufacturing medicine to treat depresion and/or disorders caused by depresion
MXPA03000429A (en) Novel aniline derivatives.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page

Free format text: UNDER (54) PUBLISHED TITLE REPLACED BY CORRECT TITLE

Free format text: UNDER (54) PUBLISHED TITLE REPLACED BY CORRECT TITLE

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002717053

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002717053

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2002717053

Country of ref document: EP